Journals / Çukurova Anestezi ve Cerrahi Bilimler Dergisi / 2021 / Cilt: 4 - Sayı: 1

Pediatric Brainstem Glioblastoma: A Systematic Review about Treatment Strategies

Pediatrik Beyin Sapı Glioblastomu: Tedavi Stratejileri Hakkında Sistematik Bir İnceleme

Pages
24–36
Publication Date
2021-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to literature, the median overall survival of these patients are approximately between 9 to 12 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Brainstem tumors are rare pathologies, brainstem glioblastoma is even rarer.
📊
Key Findings & Data:According to literature, the median overall survival of these patients are approximately between 9 to 12 months.
💡
Conclusion & Impact:Radiotherapy is associated with a decreased risk of mortality at 9 months but not long-term.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Beyin sapı · Glioblastom · Pediatrik

Abstract

Brainstem tumors are rare pathologies, brainstem glioblastoma is even rarer. We report three pediatric patients who underwent subtotal tumor resection for brainstem tumors diagnosed as brainstem glioblastoma. The clinical courses and treatment procedures were discussed alongside a comprehensive literature review. Treatment of brainstem high-grade gliomas includes steroids, surgery, radiotherapy, and chemotherapy. However, none of these treatment modalities effectively prolongs survival time. According to literature, the median overall survival of these patients are approximately between 9 to 12 months. Glioblastoma has a poor prognosis in pediatric patients with high-grade brainstem gliomas. Radiotherapy is associated with a decreased risk of mortality at 9 months but not long-term.

Özet

Beyin sapı tümörleri nadir görülen patolojilerdir, beyin sapı glioblastomu daha da nadirdir. Beyin sapı tümörleri için subtotal tümör rezeksiyonu uygulanan ve beyin sapı glioblastomu tanısı alan üç pediatrik hastayı sunmaktayız. Bu hastaların klinik gidişatlarını ve tedavi prosedürlerini, kapsamlı bir literatür taraması eşliğinde tartışmaktayız. Beyin sapında yerleşimli yüksek dereceli gliomaların tedavisinde steroidler, cerrahi rezeksiyon, radyoterapi ve kemoterapi bulunmaktadır. Bununla birlikte, bu tedavi yöntemlerinden hiçbiri hayatta kalma süresini etkili bir şekilde uzatmamaktadır. Literatüre göre, bu hastaların medyan genel sağ kalımı yaklaşık 9 ila 12 ay arasındadır. Glioblastom histopatolojisi, yüksek dereceli beyin sapı gliomaları olan pediatrik hastalarda kötü prognoz göstergesidir. Radyoterapi, uzun vadede değil ancak ilk 9 aylık süreçte mortalite riskinde azalma ile ilişkili olarak tespit edilmiştir.

🔖

Cite This Article

OKTAY, K., GUZEL, E., YAĞCI-KÜPELİ, B., GÖKSU, E., SARI, İ., GUZEL, A. (2021). Pediatric Brainstem Glioblastoma: A Systematic Review about Treatment Strategies. Çukurova Anestezi ve Cerrahi Bilimler Dergisi, Cilt: 4 - Sayı: 1, 24–36. https://ajindex.com/articles/483848

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Das KK, Mehrotra A, Nair AP, et al. Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome. Childs Nerv Syst. 2012;28(12):2055-62.
  2. Kebudi R, Cakir FB. Management of diffuse pontine gliomas in children: recent developments. Pediatr Drugs. 2013;15(5):351- 62.
  3. Kebudi R, Cakir FB, Agaoglu FY, et al. Pediatric diffuse intrinsic pontine glioma patients from a single center. Childs Nerv Syst. 2013;29(4):583-8.
  4. Veldhuijzen van Zanten SEM, Lane A, Heymans MW, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol. 2017;134(1):231-40.
  5. Mauffrey C. Paediatric brainstem gliomas: prognostic factors and management. J Clin Neurosci. 2006;13(4):431-7.
  6. Nikitovic M, Stanic D, Pekmezovic T, et al. Pediatric glioblastoma: a single institution experience. Childs Nerv Syst. 2016;32(1):97- 103.
  7. Perkins SM, Rubin JB, Leonard JR, et al. Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys. 2011;80(4):1117-21.
  8. Maxwell R, Luksik AS, Garzon-Muvdi T, et al. Population-based Study Determining Predictors of Cancer-Specific Mortality and Survival in Pediatric High-grade Brainstem Glioma. World Neurosurg. 2018;119:e1006-e1015.
  9. Klimo P Jr, Nesvick CL, Broniscer A, Orr BA, Choudhri AF. Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas. J Neurosurg Pediatr. 2016;17(1):57-65.
  10. Puget S, Beccaria K, Blauwblomme T, et al. Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Childs Nerv Syst. 2015;31(10):1773-80.
  11. Kebudi R, Cakir FB, Bay SB, et al. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Childs Nerv Syst. 2019;35(1):83-9.
  12. Bailey S, Howman A, Wheatley K, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--re